| Similar Articles |
|---|
 |
ifeminists
March 31, 2004
Tony Zizza |
GSK Uses Sports Icon as Newest Propaganda Tool Glaxo Smith Kline are masters of deception and using Terry Bradshaw as their newest propaganda tool is just more evidence of their insistence that Paxil be in every American home's medicine cabinet.   |
ifeminists
April 29, 2004
Tony Zizza |
Stop Selling Depression and Drugs To Men Author questions how it can be wrong to profile terrorists, but okay to profile a particular gender as a profitable market for medications and subjective mental health labels? |
The Motley Fool
June 3, 2004
Brian Gorman |
Spitzer Chases Glaxo Did the drug company GlaxoSmithKline withhold information about the effects of Paxil in children? No doubt the bad publicity will continue to hit the stock. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
The Motley Fool
January 19, 2011
Cliff D'Arcy |
Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements. |
Chemistry World
July 2, 2012
Andrew Turley |
$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company. |
Chemistry World
January 30, 2007
Bea Perks |
BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s. |
ifeminists
June 23, 2004
Tony Zizza |
Poor Parenting Skills Can Be A Choice It's time for Americans to start improving parenting skills from within. Stop allowing the pharmaceutical companies with their magic pills, brochures and videos to do what we alone must do - raise our children. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
The Motley Fool
March 23, 2004
W.D. Crotty |
Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks. |
The Motley Fool
March 7, 2005
Brian Gorman |
Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood. |
